Resources

GenesisCare launches MRIdian radiotherapy in the UK

Patients in the UK now have access to MRIdian, a technology from GenesisCare which combines magnetic resonance imaging (MRI) with precise radiotherapy beams. Globally, the technology has been used to treat 7,000 patients, with the greatest potential benefit being seen...

read more

Roche obtains CE mark for blood glucose monitoring app

Roche has secured CE mark for its smartphone app that allows users to measure blood glucose level without the need of a meter. Known as Accu-Chek SugarView, the app determines blood glucose ranges by taking photos with the smartphone camera. The company said that the...

read more

Leo’s Dupixent rival hits all endpoints in pivotal program

Leo Pharma’s tralokinumab has hit all the primary and secondary endpoints in its three pivotal trials. The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year, but the lack of numbers shared publicly make it impossible to...

read more

Nihon Kohden introduces new vital signs monitoring device

US-based Nihon Kohden has introduced a new portable vital signs monitoring tool with customisable early warning scoring. Designed for outpatient facilities, the Life Scope SVM-7200 Series measures blood oxygen, blood pressure and temperature. The newly launched device...

read more

Venturing A Perspective On The Drug Pricing Debate

The perennial drug pricing debate has reached a fever pitch, as loud as it’s ever been over the past few decades. Politicians on both sides are bashing the drug industry with the typical talking points about exorbitant prices, countered of course by the expected...

read more

Thinking Boldly: Alkermes Acquires Rodin Therapeutics

Today Alkermes announced its acquisition of Rodin Therapeutics, a leader in the field of synaptic dysfunction and neuronal epigenetics. Read more. The post Thinking Boldly: Alkermes Acquires Rodin Therapeutics appeared first on Atlas Venture.

read more

Ode to Patients

Due to meetings in London on a Friday and in Dortmund on the following Monday, I spent the weekend in London.  As I walked the streets appreciating its history, I could not help but think of the history of medicine, as well.  Images of leeches and...

read more

Leave No Stone Unturned: A Pipeline Story

Building a leading gene therapy pipeline in under two years (and a lot of air miles): how to persevere and make the calls that matter. Throughout a career in business development I’ve sat at every seat at the negotiating table, but I count my experience building...

read more

With eyes on IPO, muscular dystrophy startup names new CEO

The scientific founder and CEO of Cambridge startup Dyne Therapeutics has hired a new CEO — a former CFO with experience in public stock offerings. Read more. The post With eyes on IPO, muscular dystrophy startup names new CEO appeared first on Atlas Venture.

read more